Development in release testing of topical dosage forms:: use of the Enhancer Cell™ with automated sampling

被引:30
作者
Rege, PR [1 ]
Vilivalam, VD [1 ]
Collins, CC [1 ]
机构
[1] Duquesne Univ, Grad Sch Pharmaceut Sci, Dept Pharmaceut, Pittsburgh, PA 15282 USA
关键词
Enhancer cell; triamcinolone acetonide; in vitro release studies; diffusion cell; method variables; automation;
D O I
10.1016/S0731-7085(97)00184-2
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The aim of this study was to evaluate an automated method using the Enhancer Cell(TM) and compare the release of the corticosteroid triamcinolone acetonide (TA) from commercial semisolid formulations. The method used a modified USP Apparatus 2 using the Enhancer Cell(TM) in 200 ml capacity flasks instead of the standard 900 ml flasks. The additional equipment included an adapter plate to position the flasks in the center, a cover to reduce the receptor phase evaporation and smaller sized (1/4 in.) shaft and collets. All products were evaluated prior to their expiration date. Effects of system variables such as the temperature and composition of the receptor medium, stirring speed, and the choice of membrane on the drug release were evaluated. Statistical analysis was carried out using SAS Ver. 6.07 and the slopes and intercepts (of the cumulative release/unit area versus square root of time plots) were compared. TA release was a linear function of the square root of time (P less than or equal to 0.0001), in accordance with Higuchi's model (r(2) greater than or equal to 0.9 in most cases). Temperature (32 and 37 degrees C) did not affect the drug release (P > 0.32) but a significantly higher release rate was observed (P less than or equal to 0.0001) at 50 degrees C. Stirring speed (50, 100, 200 rpm) (P > 0.26) and receptor media composition (38 and 76% ethanol) (P > 0.68) did not significantly alter the release rates. Membrane selection (regenerated cellulose, polyethylene, and rat skin) was found to be a significant variable (P less than or equal to 0.004). This study demonstrates the use of the Enhancer Cell(TM) as an automated quality control tool in the in vitro release testing procedure for semisolid drug formulations. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1225 / 1233
页数:9
相关论文
共 13 条
[1]   ON THE DETERMINATION OF DRUG RELEASE RATES FROM TOPICAL DOSAGE FORMS [J].
GUY, RH ;
HADGRAFT, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 60 (02) :R1-R3
[3]   DEVELOPMENT AND VALIDATION OF METHOD FOR DETERMINATION OF INVITRO RELEASE OF RETINOIC ACID FROM CREAMS [J].
KUNDU, SC ;
CAMERON, AD ;
MELTZER, NM ;
QUICK, TW .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1993, 19 (04) :425-438
[4]  
Martin A., 1983, PHYSICAL PHARM, P399
[5]  
Sanghvi P.P., 1995, Patent No. [Patent 5408865, 5408865]
[6]  
SANGHVI PP, 1993, DRUG DEV IND PHARM, V19, P1573
[7]   INVITRO RELEASE OF HYDROCORTISONE FROM TOPICAL PREPARATIONS AND AUTOMATED PROCEDURE [J].
SHAH, VP ;
ELKINS, J ;
HANUS, J ;
NOORIZADEH, C ;
SKELLY, JP .
PHARMACEUTICAL RESEARCH, 1991, 8 (01) :55-59
[8]   IN-VITRO RELEASE FROM CORTICOSTEROID OINTMENTS [J].
SHAH, VP ;
ELKINS, JS .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (09) :1139-1140
[9]   TOPICAL CORTICOSTEROIDS - QUALITY-CONTROL CONSIDERATIONS [J].
SHAH, VP .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1992, 31 :34-37
[10]   FDA AND AAPS REPORT OF THE WORKSHOP ON PRINCIPLES AND PRACTICES OF INVITRO PERCUTANEOUS PENETRATION STUDIES - RELEVANCE TO BIOAVAILABILITY AND BIOEQUIVALENCE [J].
SKELLY, JP ;
SHAH, VP ;
MAIBACH, HI ;
GUY, RH ;
WESTER, RC ;
FLYNN, G ;
YACOBI, A .
PHARMACEUTICAL RESEARCH, 1987, 4 (03) :265-267